26 - World Journal of Gastroenterology
26 - World Journal of Gastroenterology
26 - World Journal of Gastroenterology
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
cause <strong>of</strong> liver disease in pediatric populations worldwide [1] .<br />
NAFLD comprises a disease spectrum ranging from<br />
simple steatosis to steatohepatitis (NASH), with varying<br />
degrees <strong>of</strong> inflammation and fibrosis, progressing to endstage<br />
liver disease with cirrhosis and hepatocellular carcinoma<br />
[2,3] . NAFLD affects from 2.6% to 9.8% <strong>of</strong> children and<br />
adolescents, and this figure increases up to 74% among<br />
obese individuals [4-8] . NAFLD is strongly associated with<br />
obesity, insulin resistance, hypertension, and dyslipidemia,<br />
and is now regarded as the liver manifestation <strong>of</strong> the metabolic<br />
syndrome (MetS) [9] , a highly atherogenic condition.<br />
When compared to control subjects who do not have steatosis,<br />
patients with NAFLD have a higher prevalence <strong>of</strong><br />
atherosclerosis, as shown by increased carotid wall intimal<br />
thickness, increased numbers <strong>of</strong> atherosclerotic plaques,<br />
and increased plasma markers <strong>of</strong> endothelial dysfunction,<br />
that are independent <strong>of</strong> obesity and other established risk<br />
factors [10-13] . Consistent with these observations natural history<br />
studies have reported that the increased age-related<br />
mortality observed in patients with NAFLD is attributable<br />
to cardiovascular as well as liver-related deaths [14-17] .<br />
Pathologic studies have shown that atherosclerosis<br />
is an early process beginning in childhood, with fatty<br />
streaks observed in the aorta and the coronary and carotid<br />
arteries in children and adolescents [18,19] . There is a<br />
positive correlation between the extent <strong>of</strong> early atherosclerotic<br />
lesions in the aorta and the coronary and carotid<br />
arteries and cardiovascular risk factors, including obesity,<br />
dyslipidemia, hypertension, and diabetes [20-22] . Yet the<br />
exposure to cardiovascular risk factors <strong>of</strong> children and<br />
adolescents is independently associated with an increased<br />
carotid atherosclerosis in early to middle adulthood [23,24] .<br />
Thus, the possible impact <strong>of</strong> NAFLD on cardiovascular<br />
disease (CVD) deserves particular attention in view <strong>of</strong><br />
the implications for screening/surveillance strategies in<br />
the growing number <strong>of</strong> children and adolescents with<br />
NAFLD. In the present review, we examine the current<br />
evidence on the association between NAFLD and atherosclerosis<br />
in the pediatric population, discuss briefly the<br />
possible biological mechanisms linking NAFLD and early<br />
vascular changes, and address the approach to treatment<br />
<strong>of</strong> NAFLD to prevent not only end-stage liver disease<br />
but also CVD.<br />
NAFLD AND THE METABOLIC SYNDROME<br />
NAFLD is closely associated with abdominal obesity, atherogenic<br />
dyslipidemia, hypertension, insulin resistance and<br />
impaired glucose tolerance, which are all features <strong>of</strong> the<br />
MetS. Approximately 90% <strong>of</strong> patients with NAFLD have<br />
at least one <strong>of</strong> the features <strong>of</strong> MetS, and about 33% meet<br />
the complete diagnosis, placing NAFLD as the hepatic<br />
representation <strong>of</strong> MetS [25] . The relationship <strong>of</strong> NAFLD<br />
with MetS features has been confirmed in adults in several<br />
studies [9,<strong>26</strong>-29] . Evidence for a relationship between MetS<br />
and NAFLD in children is also emerging [30-32] . The Korean<br />
National and Nutrition Examination Survey found that<br />
participants aged 10-19 years who presented with three or<br />
WJG|www.wjgnet.com<br />
Pacifico L et al . Pediatric NAFLD and cardiovascular risk<br />
more risk factors for MetS, had an odds ratio (OR) <strong>of</strong> 6.2<br />
(95% CI, 2.3-16.8) for an elevated serum alanine aminotransferase<br />
(ALT), which they used as an indicator <strong>of</strong> fatty<br />
liver [30] . A single center study from Italy reported MetS to<br />
be present in 65.8% <strong>of</strong> children (3-18 years) with biopsyproven<br />
NAFLD and found grade <strong>of</strong> fibrosis to be the only<br />
histological feature significantly associated with MetS on<br />
univariate analysis [31] . A case-control study comparing 150<br />
overweight children with biopsy-proven NAFLD to 150<br />
age-, sex-, and obesity-matched children without evidence<br />
<strong>of</strong> NAFLD, found that, after adjustment for age, sex, race,<br />
ethnicity, and hyperinsulinemia, children with MetS had<br />
an OR <strong>of</strong> 5.0 (95% CI, 2.6-9.7) for NAFLD compared<br />
with children without MetS [32] . This is the most compelling<br />
data to support a significant relationship between NAFLD<br />
and MetS, not explicable merely by the coexistence <strong>of</strong><br />
overweight or obesity in these two conditions, and lend<br />
support to the hypothesis that fat accumulation in the liver<br />
has an important role in the pathogenesis <strong>of</strong> other obesityrelated<br />
comorbidities [33] .<br />
NAFLD AND CARDIOVASCULAR DISEASE<br />
Increases in morbidity and mortality from CVD are probably<br />
among the most important clinical features associated<br />
with NAFLD [13] . Published studies have shown that mortality<br />
among patients with NAFLD is higher than that in<br />
the general population, mainly due to concomitant CVD<br />
and liver dysfunction [14-17] . Using the resources <strong>of</strong> the Rochester<br />
Epidemiology Project, Adams et al [14] conducted a<br />
population-based cohort study to examine the natural history<br />
<strong>of</strong> patients diagnosed with NAFLD on the basis <strong>of</strong><br />
imaging studies (83%) or liver biopsy (17%). Mean (SD)<br />
follow-up was 7.6 (4.0) years culminating in 3192 persons/<br />
years follow-up. Death occurred in 12.6% <strong>of</strong> patients and<br />
was most commonly due to malignancy and ischemic heart<br />
disease, which were also the two most common causes <strong>of</strong><br />
death in the Minnesota general population <strong>of</strong> the same<br />
age and sex. Liver disease was also an important contributor<br />
<strong>of</strong> death among patients with NAFLD, being the third<br />
most common cause and accounting for 13% <strong>of</strong> all deaths.<br />
In contrast, “chronic liver disease and cirrhosis” was the<br />
13th leading cause <strong>of</strong> death among the Minnesota general<br />
population, accounting for less than 1% <strong>of</strong> all deaths [14] .<br />
This implies that the increased overall mortality rate among<br />
NAFLD patients compared with the general population<br />
was at least in part due to complications <strong>of</strong> NAFLD. In a<br />
cohort study involving 129 consecutively enrolled patients<br />
diagnosed with biopsy-proven NAFLD, Ekstedt et al [15]<br />
compared survival and causes <strong>of</strong> death with a matched<br />
reference population. Mean follow-up (SD) was 13.7 (1.3)<br />
years. Mortality was not increased in patients with steatosis.<br />
In contrast, survival <strong>of</strong> patients with NASH was significantly<br />
reduced. A comparison <strong>of</strong> the causes <strong>of</strong> death <strong>of</strong><br />
patients with NASH with those <strong>of</strong> the corresponding<br />
reference population showed it was significantly more<br />
common for patients with NASH to die from liver-related<br />
causes (2.8% vs 0.2%) and from cardiovascular disease<br />
3083 July 14, 2011|Volume 17|Issue <strong>26</strong>|